Caplin Steriles (subsidiary) secured USFDA final approval for Potassium Phosphates Injection.

Caplin Point Laboratories LimitedCAPLIPOINT · Filed with the exchange

This generic targets a US market with annual sales of $57 million (~₹5.7 Cr), significantly expanding Caplin Point's product portfolio and market reach.

Read the original filing(PDF)

No comments yet. Be the first.

More from Caplin Point Laboratories Limited

All announcements

Others04-09-2026
Copy of Newspaper Publication
Important04-09-2026
Updates
Important03-09-2026
Updates
Others03-09-2026
Shareholders meeting
Others02-09-2026
Spurt in Volume
Others02-09-2026
Copy of Newspaper Publication

Free

Track this company, and every filing it makes

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

Create a free account

No card needed. Takes about a minute.